Dr. Lal PathLabs Limited’s Board of Directors has approved the declaration of a second interim dividend of INR 5 per equity share for the financial year 2026-27. Additionally, the board greenlit a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), for its business and operational requirements, including onward investment in Sunshine Healthcare Limited.
Board Approves Interim Dividend and Subsidiary Investment
In a board meeting held on November 04, 2026, Dr. Lal PathLabs Limited announced several key financial and strategic decisions. The board has declared a second interim dividend of INR 5 per equity share, representing a 50% payout on the face value of INR 10 each, for the financial year 2026-27. The record date for this dividend payment has been set for November 11, 2026, and the dividend will be paid within 30 days of its declaration.
Strategic Investment in LPL Dubai
The board also approved a significant investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai). This investment, to be made in one or more tranches, is intended to meet LPL Dubai’s business and operational needs, including further investment in its subsidiary, Sunshine Healthcare Limited (SHL) in Ghana. LPL Dubai, incorporated on June 12, 2026, serves as a strategic vehicle for investments in diagnostics and allied activities.
Appointment of New Director
Further to these financial decisions, the Board, based on the recommendation of the Nomination and Remuneration Committee, appointed Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director. Ms. Agarwal will serve as a Non-Executive Independent Director for a term of three consecutive years, commencing November 04, 2026, subject to shareholder approval via postal ballot. Ms. Agarwal is a notable business and technology leader with extensive experience in artificial intelligence and digital advertising.
Financial Results
The board also considered and approved the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. A signed copy of these results, along with the Limited Review Report from the Statutory Auditors, is attached as Annexure-A.
The Board Meeting commenced at 11:49 A.M. (IST) and concluded at 01:20 P.M. (IST).
Source: BSE
